{"id":391638,"date":"2014-05-27T00:00:00","date_gmt":"2014-05-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0714-biopharma-the-impact-of-eu5-payer-policy-on-prescribing-in-non-hodgkins-lymphoma-and-multiple-myeloma\/"},"modified":"2026-03-31T09:05:14","modified_gmt":"2026-03-31T09:05:14","slug":"pforeu0714-biopharma-the-impact-of-eu5-payer-policy-on-prescribing-in-non-hodgkins-lymphoma-and-multiple-myeloma","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0714-biopharma-the-impact-of-eu5-payer-policy-on-prescribing-in-non-hodgkins-lymphoma-and-multiple-myeloma\/","title":{"rendered":"The Impact of EU5 Payer Policy on Prescribing in Non-Hodgkin\u2019s Lymphoma and Multiple Myeloma | Physician &#038; Payer Forum | EU5 | 2014"},"content":{"rendered":"<p>In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents\u2014Janssen\u2019s Velcade (bortezomib), Celgene\u2019s Revlimid (lenalidomide), and Celgene\u2019s Thalidomide (thalidomide)\u2014while the treatment for non-Hodgkin\u2019s lymphoma (NHL) has Roche\u2019s MabThera (rituximab) as a central player. All of these drugs have demonstrated clear improvements in clinical practice and have achieved significant commercial success within their indications. Multiple emerging agents spanning several different dug classes are in development for MM and NHL. Although many of these emerging therapies appear clinically promising, they face considerable competition from currently available therapies. The presence of several promising agents in development, coupled with dynamic markets, make the MM and NHL indications very exciting from a commercial, as well as a clinical point of view.<\/p>\n","protected":false},"template":"","class_list":["post-391638","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391638\/revisions"}],"predecessor-version":[{"id":577026,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391638\/revisions\/577026"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}